The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Much Is The Conjugate Vaccine Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?
The conjugate vaccine market size has seen rapid expansion in recent years. It is anticipated to grow from $21.26 billion in 2025 to $23.84 billion in 2026, reflecting a compound annual growth rate (CAGR) of 12.1%. This historical growth can be attributed to several factors, including government-led immunization initiatives, a high prevalence of bacterial infections, support from global health organizations, the proven efficacy of conjugate vaccines, and an increasing pediatric population.
The conjugate vaccine market is projected to experience swift expansion in the coming years. By 2030, this market is set to reach $38.54 billion, exhibiting a compound annual growth rate (CAGR) of 12.8%. The expansion during this forecast timeframe is driven by factors such as increasing demand for combination vaccines, the broadening of adult vaccination programs, enhanced funding for vaccine research and development (R&D), a heightened focus on antimicrobial resistance, and improvements in cold chain infrastructure. Key trends expected in the forecast period encompass the growth of pediatric immunization initiatives, a greater uptake of multivalent conjugate vaccines, an intensified emphasis on long-term immunogenicity, an increase in public-private collaborations for vaccines, and progress in carrier protein technologies.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10850&type=smp
What Drivers Are Influencing The Conjugate Vaccine Market?
The conjugate vaccine market is projected to grow significantly, driven by the increasing occurrence of infectious diseases. These conditions are illnesses resulting from pathogenic microorganisms such as bacteria, viruses, parasites, or fungi, which can be transmitted directly or indirectly between people, from animals to humans, or via the environment. Conjugate vaccines are essential for preventing bacterial infectious diseases, especially in vulnerable demographics like infants and young children. For instance, reports from the Centers for Disease Control and Prevention, a U.S.-based governmental body, show that tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, marking an addition of 1,295 cases. Moreover, the incidence rate moved from 2.5 per 100,000 individuals in 2022 to 2.9 in 2023. Therefore, the rising prevalence of infectious diseases is a key factor boosting the conjugate vaccine market’s expansion.
What Major Segment Divisions Exist Within The Conjugate Vaccine Market?
The conjugate vaccine market covered in this report is segmented –
1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine
2) By Pathogen: Bacterial, Viral
3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid
4) By Patient: Pediatric, Adults
5) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users
How Are Trends Shaping The Direction Of The Conjugate Vaccine Market?
Major companies operating in the conjugate vaccine market are actively developing next-generation conjugate vaccines to ensure more extensive protection against multiple pneumococcal serotypes, thereby reducing the disease burden among vulnerable populations. These advanced conjugate vaccines work by attaching bacterial polysaccharides to carrier proteins to boost the immune response, especially in infants and immunocompromised individuals, offering enhanced protection, prolonged immunity, and greater effectiveness compared to traditional vaccines. For instance, in August 2025, Pfizer Ltd., an India-based pharmaceutical company, introduced its next-generation 20-valent Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) I.P., PCV20, for adults in India, which strengthens its conjugate vaccine portfolio by providing broader protection against pneumococcal disease and supporting improved public health outcomes.
Which Companies Are Leading Innovation In The Conjugate Vaccine Market?
Major companies operating in the conjugate vaccine market are Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus
Read the full conjugate vaccine market report here:
https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report
Which Regions Are Expected To Experience Rapid Expansion In The Conjugate Vaccine Market?
North America was the largest region in the global conjugate vaccine market in 2025. The regions covered in the conjugate vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Conjugate Vaccine Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=10850&type=smp
Browse Through More Reports Similar to the Global Conjugate Vaccine Market 2026, By The Business Research Company
Conjugate Vaccine Market Report 2026
https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report
Vaccine Adjuvants Market Report 2026
https://www.thebusinessresearchcompany.com/report/vaccine-adjuvants-global-market-report
Vaccines Market Report 2026
https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model